Exelixis Inc. Aktie
32,82 €
Deine Einschätzung
Exelixis Inc. Aktie
Was spricht für und gegen Exelixis Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Exelixis Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Exelixis Inc. | 2,63 % | -15,49 % | -14,26 % | 49,86 % | -2,02 % | 56,19 % | 53,71 % |
Ironwood Pharmaceuticals | 2,01 % | 2,26 % | 14,29 % | -89,21 % | -83,81 % | -94,35 % | -91,23 % |
Novocure Ltd | -0,55 % | -29,02 % | -35,99 % | -48,78 % | -66,18 % | -85,20 % | -82,95 % |
Iovance Biotherapeutics Inc. | -2,61 % | -5,38 % | 74,90 % | -69,70 % | -63,33 % | -77,79 % | -89,60 % |
Kommentare
News

Exelixis Stock: Mixed Signals After Earnings Beat
Biotech company Exelixis delivered notably mixed second-quarter 2025 results, creating divergent investor reactions. The California-based firm reported earnings per share of $0.75, significantly

Exelixis Q2 Revenue Falls 11 Percent
Exelixis (NASDAQ:EXEL), an oncology-focused biotech, reported results for Q2 2025 on July 28, 2025. For the period, the company delivered non-GAAP earnings per share (EPS) of $0.75 in Q2 FY2025

Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45